麻豆果冻传媒影音

A post hoc analysis of the phase III showed that the addition of daratumumab (Darzalex) to lenalidomide (Revlimid) for multiple myeloma in the post-transplant maintenance setting improved minimal residual disease (MRD)-negativity conversion rates compared with lenalidomide alone across clinically relevant subgroups.

In this exclusive MedPage Today video, Laahn Foster, MD, of the University of Virginia in Charlottesville, discusses the results of the analysis, which was presented at the recent American Society of Hematology annual meeting.

Following is a transcript of her remarks:

I presented the subgroup analysis on the phase III AURIGA study, and basically the AURIGA study is looking at the addition of daratumumab to lenalidomide maintenance in the post-transplant setting in newly diagnosed multiple myeloma patients.

So the that was presented at IMS [the International Myeloma Society annual meeting] earlier this year showed a statistically significant improvement in MRD-negative conversion rates for patients that were treated with [daratumumab/lenalidomide] versus [lenalidomide]. And so this particular abstract was looking at the different subgroups, so looking at disease or patient characteristics, age, race, and also the ISS [International Staging System] staging, [and] also looking at different cytogenetic risk classifications by a number of different ways that we've sliced the data.

Overall, makes it pretty simple, is that there was a benefit in adding daratumumab to lenalidomide maintenance in the post-transplant setting. It seemed to improve MRD negativity rates across all the different subgroups, so, despite age, race, ISS stage, their response at diagnosis, and the different risk classifications for cytogenetic risk.

It shows that there's a benefit in using a doublet kind of regimen in the maintenance setting, specifically in this particular study looking at daratumumab and lenalidomide. So that I think would be the overall conclusion. And it basically just supports, or is complementary to, the data that was published for PERSEUS and GRIFFIN. So I think overall that's what I would say.

Comment